Delta Secretase and BDNF Signalling in Alzheimer's Disease

被引:0
|
作者
Unlu, Buse [1 ]
Ildiz, Sumeyra [1 ]
Ak, Duygu Gezen [1 ]
Dursun, Erdinc [1 ]
机构
[1] Istanbul Univ Cerrahpasa, Inst Neurol Sci, Dept Neurosci, Istanbul, Turkiye
来源
EXPERIMED | 2023年 / 13卷 / 01期
关键词
BDNF; axonal transport; delta secretase; Alzheimer's disease; APP; tau protein; AXONAL-TRANSPORT; TAU; PHOSPHORYLATION; RECEPTORS; CLEAVAGE; LEGUMAIN; BETA;
D O I
10.26650/experimed.1231893
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
As one of the major contributors of the central nervous system, neurons require neurotrophic factors, which are synthesized from neighbouring cells, for several cellular processes, such as neuronal survival, growth, and differentiation. Neurotrophic factors are categorized into the neurotrophin family, the neuropoietic cytokines, and the glial cell-derived neurotrophic factor. The neurotrophin family comprises four growth factors: nerve growth factor (NGF), neurotrophin-3 (NT3), neurotrophin-4 (NT4), and brain-derived neurotrophic factor (BDNF). One of the best-known neurotrophic factors is BDNF. Its importance is based on its central role in neuronal survival. Entry of the BDNF into the neurons occurs via TrkB receptors, and it is transported to the cell body along microtubules in axons. As it is known in the brains of Alzheimer's patients, the axonal transport of BDNF is destructed via the hyperphosphorylated tau. There are several causes for the hyperphosphorylation of tau. Among them, delta secretase (delta-secretase), a lysosomal cysteine protease, cleaves both amyloid precursor protein (APP) and tau. It is supposed to play an essential role in tau hyperphosphorylation, particularly in the aging brain. In this review, we focus on the activity of delta-secretase, how it leads to tau hyperphosphorylation, and how it disrupts the axonal transport of BDNF in Alzheimer's disease.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] Targeting both BDNF/TrkB pathway and delta-secretase for treating Alzheimer's disease
    Liao, Jianming
    Chen, Chun
    Ahn, Eun Hee
    Liu, Xia
    Li, Hua
    Edgington-Mitchell, Laura E.
    Lu, Zhonghua
    Ming, Shuping
    Ye, Keqiang
    NEUROPHARMACOLOGY, 2021, 197
  • [2] γ-Secretase in Alzheimer’s disease
    Ji-Yeun Hur
    Experimental & Molecular Medicine, 2022, 54 : 433 - 446
  • [3] γ-Secretase inhibitors and Alzheimer's disease
    Roberts, SB
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (12) : 1579 - 1588
  • [4] Targeting γ-secretase for Alzheimer's disease
    Wolfe, Michael S.
    Alzheimer: 100 Years and Beyond, 2006, : 265 - 268
  • [5] β-secretase -: A target for Alzheimer's disease
    Citron, M
    MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 79 - 83
  • [6] Alzheimer's disease:: β-amyloid and γ-secretase
    Iwatsubo, Takeshi
    NEUROBIOLOGY OF AGING, 2008, 29 : S13 - S13
  • [7] Secretase inhibitors for Alzheimer's disease
    Kornilova, AY
    Wolfe, MS
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 38, 2003, 38 : 41 - 50
  • [8] Alzheimer's disease -: In search of γ-secretase
    Hardy, J
    Israël, A
    NATURE, 1999, 398 (6727) : 466 - 467
  • [9] Alzheimer's disease -: Closing in on γ-secretase
    De Strooper, B
    NATURE, 2000, 405 (6787) : 627 - 629
  • [10] Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer's Disease
    Wang, Zhi-Hao
    Xiang, Jie
    Liu, Xia
    Yu, Shan Ping
    Manfredsson, Fredric P.
    Sandoval, Ivette M.
    Wu, Shengxi
    Wang, Jian-Zhi
    Ye, Keqiang
    CELL REPORTS, 2019, 28 (03): : 655 - +